PF-04958242 clinical trials

Studies by the year they started

17 studies that test it; most in 2011 (4)

Who runs them

Industry 17 · Other 0

Biogen (17)

Often tested with

Tested in the same studies.

Itraconazole (1)

Studies

Open first, then newest update. How each study uses PF-04958242 is read from its arms, and is right about nine times in ten.

Testing it · 17

• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)CompletedPhase 2BiogenNCT03745820Written as BIIB104
• A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedPhase 1BiogenNCT05148481Written as BIIB104
• A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy ParticipantsCompletedPhase 1BiogenNCT05152485Written as BIIB104 Reference Formulation
• Multiple Ascending Doses of PF-04958242 in Subjects With Stable SchizophreniaCompletedPhase 1BiogenNCT02332798Written as PF-04958242
• Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese ParticipantsCompletedPhase 1BiogenNCT04079101Written as BIIB104
• A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy ParticipantsCompletedPhase 1BiogenNCT04068532Written as BIIB104
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy SubjectsCompletedPhase 1BiogenNCT02341482Written as PF-04958242
• A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)TerminatedPhase 2BiogenNCT02855411Written as PF-04958242
• Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy VolunteersCompletedPhase 1BiogenNCT02228395Written as PF-04958242
• A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy SubjectsCompletedPhase 1BiogenNCT01365338Written as PF-04958242
• First-in-Human Study of PF-04958242 in Healthy VolunteersCompletedPhase 1BiogenNCT01159483Written as PF-04958242
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult VolunteersTerminatedPhase 1BiogenNCT01238679Written as PF-04958242
• A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing LossCompletedPhase 1BiogenNCT01518920Written as PF-04958242
• A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With SchizophreniaCompletedPhase 1BiogenNCT01518894Written as PF-04958242
• Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution FormulationCompletedPhase 1BiogenNCT01646840Written as PF-04958242 capsule
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy VolunteersCompletedPhase 1BiogenNCT01511510Written as PF-04958242
• A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy VolunteersCompletedPhase 1BiogenNCT01749098Written as PF-04958242

Codes

What other systems call PF-04958242 · ClinicalTrials.gg INT000305

• UNII (FDA) 9G1A824CC2PESAMPATORConfirmed FDA, Wikidata
• Wikidata Q27272515PF-04958242Confirmed FDA, Wikidata
• DrugBank DB11843One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.